651734-51-9Relevant academic research and scientific papers
SULFONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Paragraph 00306; 00307, (2021/01/29)
Provided herein are sulfone compounds, for example, a compound of Formula A, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition.
USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS
-
Page/Page column 25; 26, (2010/10/20)
This invention provides methods for utilizing compounds that inhibit cyclin-dependent kinase and tyrosine kinase enzymes in the promotion of neochondrogenesis and the enhancement, protection and repair of cartilage. In certain embodiments the invention relates to methods of using compounds of formula (I): and pharmaceutically acceptable salts thereof, to promote neochondrogenesis, wherein, R1,R2, R3, R4, R5, R6, A, B, D, and E have any of the values defined therefor in the specification.
Kinase inhibitors
-
Page 12, (2010/11/30)
This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis, as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.
